evaluating drug induced proarrhythmic risk using the cardioecr system
Published 8 years ago • 339 plays • Length 24:33Download video MP4
Download video MP3
Similar videos
-
1:15
cardiotoxicity screening using hipsc cardiomyocytes and acea's xcelligence cardioecr sysem
-
7:10
innovations series with acea bioscience's xcelligence cardioecr system
-
57:01
webinar: exploring the role of ipsc-cardiomyocytes in drug discovery and safety assessment
-
40:13
cardiac proarrhythmic risk assessment using human ipsc-derived cardiomyocytes - session 1
-
28:27
innovations w/ed begley, jr featuring acea's rtca xcelligence cardioecr system- intv1218
-
49:20
cardiac toxicity assessment using stem cell derived cardiomyocytes
-
42:06
cardiac proarrhythmic risk assessment using human ipsc-derived cardiomyocytes - session 2
-
36:18
integrated cardiac proarrythmic risk assessment under the cipa initative [2020 jsps seminar]
-
1:39:06
how i treat autoinflammatory disorders: clinical approach to systemic autoinflammatory disorders
-
7:23
tophat autonomic acetylcholine and norepinephrine
-
1:01:21
coding an operative report part ii: cardiovascular system
-
47:54
eurofins integrated cardiac proarrythmic risk assessment under the cipa initiative
-
2:06
xcelligence – a transformative technology in cancer research (2/2)
-
21:40
validation of htp assays using human ipsc-derived cardiomyocytes to assess cardiotoxic compounds
-
51:55
electrical field stimulation for the functional maturation of hipsc-cardiomyocytes
-
3:32
new risk factors for afib, duration of anticoagulation for avr
-
2:36
administering antidysrhythmics
-
1:21
what rhythm control medication options are there for those with heart disease?
-
26:07
clinical applications for the quest with modificatations
-
2:41
introduction to the devices clinic
-
19:06
cardiac rhythm management devices & energy-based devices
-
5:57
management of atrial fibrillation | dr. k kannanan | zydus medica revolutiontalk | therightdoctors